Loading company
$2.32-2.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 27, 2026
Past performance
- 1W
- +4.0%
- 1M
- +7.4%
- 3M
- +160%
- 6M
- -7.6%
- 1Y
- +28.9%
- 5Y
- -55.4%
$2.32-2.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 27, 2026
Just reported
From Nautilus Biotechnology, Inc.'s results release of October 27, 2026; its quarterly report has since been filed.
Actual
$234K
+23% q/q
Guided
—
No guide given
Actual
-$0.12
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Profit | -$15.6M | -$13.6M | -15.19% |
| Profit per share | -$0.12 | -$0.11 | -9.09% |
| Free Cash Flow | -$14.7M | -$11.5M | -28.59% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Nautilus Biotechnology, Inc. has no earnings call transcript available.
“The third quarter marked an important step in demonstrating the power and scalability of Iterative Mapping on our Voyager platform,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Biotechnology, Inc. With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio 1 Special Note Regarding
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Nautilus Biotechnology, Inc.’s Item 2.02 8-K filed October 27, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.